BioCryst Pharma Sells European Business for Rare Disease Drug in $250M Deal

Neopharmed buys Euro rights to BioCryst's HAE drug Orladeyo

Neopharmed Gentili buys BioCryst's hereditary angioedema drug Orladeyo in Europe, the first stage of an international expansion for the Italian firm.

BioCryst Pharma Sells European Business for Rare Disease Drug in $250M Deal

Neopharmed Gentili is acquiring European rights to Orladeyo, bringing the Italy-based pharmaceutical company into rare disease. BioCryst’s Orladeyo is approved for treating patients with the rare disease hereditary angioedema. The post BioCryst Pharma Sells European Business for Rare Disease Drug in $250M Deal appeared first on MedCity News.

BioCryst Pharma Sells European Business for Rare Disease Drug in $250M Deal – RamaOnHealthcare

Neopharmed Gentili is acquiring European rights to Orladeyo, bringing the Italy-based pharmaceutical company into rare disease. BioCryst’s Orladeyo is approved for treating patients with the rare disease hereditary angioedema.BioCryst Pharmaceuticals is selling the European rights and assets for its top product for $250 million, cash that the rare disease drug developer will use to pay [...]